GC101 TIL

BIOLOGICAL2 trials

Sponsors

Shanghai Juncell Therapeutics

Conditions

Adverse Drug EventEfficacyMelanomaSafetyTumor Infiltrating Lymphocytes

Phase 1

A Study of GC101 TIL in Advanced Melanoma (BZ)

CompletedNCT06120712

Shanghai Juncell TherapeuticsAdverse Drug Event, Efficacy, Melanoma +2

Start: 2023-11-08End: 2025-11-12Updated: 2025-12-23

Phase 2

A Study of GC101 TIL in Advanced Melanoma

RecruitingNCT06703398

Shanghai Juncell TherapeuticsMelanoma

Start: 2024-12-20End: 2027-12-20Target: 98Updated: 2026-08-05

Related Papers

A multicenter, randomized, controlled, open-label, phase II trial of autologous tumor-infiltrating lymphocytes (GC101 TIL) in patients with advanced melanoma.

Journal of Clinical Oncology2026-06-03